Adam Bryant

Our Direct Lending team has provided senior debt facilities to support Keensight Capital's acquisition of Bedfont Scientific Ltd, a leader in non-invasive breath diagnostics. This marks our first transaction with Keensight, reflecting our continued support for ambitious growth across the healthcare sector. Read more: https://lnkd.in/djmh3ree

130

1 Comment

“It has the potential to stop or slow Parkinson’s.” NRG Therapeutics has secured an impressive £50 million to advance their drug, NRG5051, into clinical trials for people with Parkinson’s. The Parkinson’s UK Virtual Biotech originally invested £1 million in 2019, and is now working in partnership with the Parkinson's Foundation. Dr Lynsey Bilsland is here to tell you more about the drug, how we remain an active founding investor and the next steps.

219

10 Comments

Nuclide Therapeutics, a British BioTech company and King's College London spin-out focused on developing targeted radiopharmaceuticals for therapy-resistant cancers, has raised €5.7 million in funding 🇬🇧🎗 The round saw participation from Marathon Beteiligungs AG, in what is reportedly the largest pre-money valuation of any King’s College London spin-out to date. Muhammet Tanc PhD, Co-founder, and CEO of Nuclide Therapeutics, commented: “The launch of Nuclide Therapeutics marks a bold step forward in our mission to give therapy-resistant cancer patients an effective treatment option.” https://lnkd.in/dnRnH6We

103

2 Comments

We're pleased to announce a £5 million investment into Cyted Health, a leading gastrointestinal molecular diagnostics company, as part of an £32.5 million Series B funding round. The round was co-led with EQT Life Sciences and Advent Life Sciences, with continued support from existing investors Morningside and BGF. Founded by leading experts at the University of Cambridge, Cyted is pioneering the development of minimally invasive cell collection coupled with proprietary biomarker discovery to transform the detection of pre-cancerous, cancerous and inflammatory esophageal conditions. "Life sciences is an area of real opportunity for the UK. We have an abundance of high potential, IP rich companies that can become market leaders if they have the funding needed to scale. This is why life sciences is one of the eight key sectors included in the Government’s Industrial Strategy," says Leandros Kalisperas, our Chief Investment Officer. "The British Business Bank is already the most active investor in UK life sciences, but the sector will continue to be a priority for our investment to ensure companies like Cyted can grow and fulfil their potential."

135

1 Comment

Everyone in biotech knows the Oxford, Cambridge, London golden triangle of UK life sciences. BiotechTV’s UK correspondent, Amy Brown, described why more people need to also know about Stevenage as she visits the Stevenage Bioscience Catalyst. BiitechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | Klein Hersh | Savills | NYSE | Genezen

72

With the National Cancer Plan expected in the coming months, its contents sparked discussions on the sidelines of the Labour Party Conference.   John McNeill, Oncology Business Unit Director at MSD in the UK, explores in The House Magazine how the Plan can truly improve care and outcomes for cancer patients across England.   From reducing disparity in care to preparing for the next generation of treatments, the National Cancer Plan presents a rare opportunity to address the challenges facing cancer patients in England today and enable the NHS for tomorrow.   See below three elements we believe the Plan should deliver on👇and read the full article here 👉 http://bit.ly/4ogj63z   GB-NON-11930

54

Enhanced Genomics has completed a funding round that extends its total Series A raise to $19 million. Backers were BGF, Parkwalk Advisors and Meltwind Advisory LLP. The company, based at St John's Innovation Park in Cambridge, pioneers 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases. The funding will be used to expand Enhanced’s internal therapeutic pipeline in common diseases, including autoimmune conditions such as inflammatory bowel disease. It will enable the company to scale its output through strategic partnerships with pharma and biotech, leveraging novel target identification and asset-based opportunities to drive long-term growth. Enhanced Genomics Chair, Dietrich Stephan, said: “Our founders have led the field by developing technology to map 3D interactions on a whole-genome scale and integrating these data with comprehensive multi-omics datasets. “We now have the technological capabilities to decipher the causal biology that drives complex and common genetic diseases, with the potential to develop truly effective new blockbuster therapies. “This puts us in a strong position to lead the next major shift in pharma. When developing a novel approach to drug discovery, clarity of thought and courage are required to build deep conviction and we are proud to have built a team that embodies this.” Full article – https://lnkd.in/eBBcbsBb

60

4 Comments

"We aspire to move faster than other countries and really set the standards,” MHRA CEO Lawrence Tallon says in new interview with the Financial Times as he sets out his ambitions for the agency. By streamlining processes and removing duplicative work through schemes like International Recognition, the agency will spend more time on staking out a global lead in areas where the UK has "deep expertise", such as AI in healthcare, and cell and gene therapies. Read the full story: http://bit.ly/46kOF6u

135

2 Comments